Sanofi snaps up inhaled insulin licence


Pharma major Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialise Mannkind’s recently-approved Afrezza inhaled insulin powder for global distribution.

Sanofi will pay $150 million (£89 million) up front, plus up to $775 million in performance milestones. Mannkind will continue to manufacture the product, but Sanofi will cover regulatory and development activities, including expanding manufacturing capacity.


Related Content

Inhaled insulin approved in US

30 June 2014 Business

news image

European committee recommends approval for generic long-acting insulin

Going up in vapour

15 April 2016 Premium contentFeature

news image

As research suggests that e-cigarettes may expose vapers to harmful chemicals, Rebecca Trager finds that governments are catc...

Most Commented

Crawling chemical system acts as if it’s alive

24 May 2016 Research

news image

Intriguing globule that moves, eats and defecates

Let's see that again

27 May 2016 In the Pipeline

news image

Has chemistry evaded the reproducibility crises affecting other branches of science? Or is it just a question of scale, asks ...